Anupam Rama
Stock Analyst at JP Morgan
(4.38)
# 336
Out of 5,152 analysts
299
Total ratings
49.21%
Success rate
20.15%
Average return
Main Sectors:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGMB AgomAb Therapeutics NV | Initiates: Overweight | $32 | $13.76 | +132.56% | 1 | Mar 3, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $177 → $176 | $129.44 | +35.97% | 21 | Feb 17, 2026 | |
| ZLAB Zai Lab | Maintains: Overweight | $46 → $39 | $19.30 | +102.07% | 13 | Feb 5, 2026 | |
| VERA Vera Therapeutics | Maintains: Overweight | $99 → $96 | $38.86 | +147.04% | 12 | Dec 19, 2025 | |
| COGT Cogent Biosciences | Maintains: Overweight | $65 → $67 | $37.45 | +78.91% | 9 | Dec 19, 2025 | |
| VOR Vor Biopharma | Maintains: Overweight | $43 → $40 | $14.52 | +175.58% | 2 | Dec 19, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $147 → $145 | $100.01 | +44.99% | 7 | Dec 19, 2025 | |
| NVAX Novavax | Maintains: Underweight | $7 → $6 | $9.96 | -39.76% | 1 | Nov 18, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $17 → $20 | $13.85 | +44.40% | 7 | Nov 18, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $29 → $32 | $22.56 | +41.84% | 6 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $13.74 | +23.73% | 1 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $33 | $21.51 | +53.42% | 11 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $27 | $12.78 | +111.27% | 5 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $77 | $66.20 | +16.31% | 12 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $14.34 | +32.54% | 14 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $11 | $5.63 | +95.56% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $36 | $20.13 | +78.84% | 18 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 → $24 | $25.18 | -4.69% | 8 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $79 | $33.02 | +139.29% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 | $7.04 | +56.36% | 12 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $37 | $45.30 | -18.32% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.60 | - | 1 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $24 | $16.22 | +48.01% | 17 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $80 | $57.30 | +39.63% | 12 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $117 | $21.46 | +445.20% | 3 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $27.32 | +61.05% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $46.04 | -13.12% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.36 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.90 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.77 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $5.43 | +139.41% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $5.05 | +4,850.50% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.17 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $62.26 | -6.84% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $13.59 | -11.70% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $9.10 | +306.82% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $91.41 | -39.83% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $14 → $38 | $10.16 | +274.02% | 13 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $15.54 | +80.18% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $27.63 | +95.44% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.17 | +26,370.59% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $15.21 | +77.51% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $320.51 | -57.26% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $7.14 | +572.27% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.91 | +3,190.56% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $63.20 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.63 | - | 2 | Jul 21, 2017 |
AgomAb Therapeutics NV
Mar 3, 2026
Initiates: Overweight
Price Target: $32
Current: $13.76
Upside: +132.56%
Neurocrine Biosciences
Feb 17, 2026
Maintains: Overweight
Price Target: $177 → $176
Current: $129.44
Upside: +35.97%
Zai Lab
Feb 5, 2026
Maintains: Overweight
Price Target: $46 → $39
Current: $19.30
Upside: +102.07%
Vera Therapeutics
Dec 19, 2025
Maintains: Overweight
Price Target: $99 → $96
Current: $38.86
Upside: +147.04%
Cogent Biosciences
Dec 19, 2025
Maintains: Overweight
Price Target: $65 → $67
Current: $37.45
Upside: +78.91%
Vor Biopharma
Dec 19, 2025
Maintains: Overweight
Price Target: $43 → $40
Current: $14.52
Upside: +175.58%
Nuvalent
Dec 19, 2025
Maintains: Overweight
Price Target: $147 → $145
Current: $100.01
Upside: +44.99%
Novavax
Nov 18, 2025
Maintains: Underweight
Price Target: $7 → $6
Current: $9.96
Upside: -39.76%
ORIC Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $13.85
Upside: +44.40%
Olema Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $29 → $32
Current: $22.56
Upside: +41.84%
Nov 14, 2025
Initiates: Overweight
Price Target: $17
Current: $13.74
Upside: +23.73%
Nov 12, 2025
Maintains: Overweight
Price Target: $40 → $33
Current: $21.51
Upside: +53.42%
Nov 7, 2025
Maintains: Overweight
Price Target: $26 → $27
Current: $12.78
Upside: +111.27%
Nov 7, 2025
Maintains: Overweight
Price Target: $76 → $77
Current: $66.20
Upside: +16.31%
Nov 6, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $14.34
Upside: +32.54%
Nov 5, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $5.63
Upside: +95.56%
Nov 5, 2025
Maintains: Overweight
Price Target: $40 → $36
Current: $20.13
Upside: +78.84%
Oct 24, 2025
Upgrades: Overweight
Price Target: $15 → $24
Current: $25.18
Upside: -4.69%
Oct 23, 2025
Maintains: Overweight
Price Target: $74 → $79
Current: $33.02
Upside: +139.29%
Oct 20, 2025
Upgrades: Neutral
Price Target: $11
Current: $7.04
Upside: +56.36%
Sep 29, 2025
Maintains: Overweight
Price Target: $27 → $37
Current: $45.30
Upside: -18.32%
Sep 16, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.60
Upside: -
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $16.22
Upside: +48.01%
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $57.30
Upside: +39.63%
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $21.46
Upside: +445.20%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $27.32
Upside: +61.05%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $46.04
Upside: -13.12%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $2.36
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $10.90
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $4.77
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $5.43
Upside: +139.41%
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $5.05
Upside: +4,850.50%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $8.17
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $62.26
Upside: -6.84%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $13.59
Upside: -11.70%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $9.10
Upside: +306.82%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $91.41
Upside: -39.83%
Oct 11, 2021
Upgrades: Neutral
Price Target: $14 → $38
Current: $10.16
Upside: +274.02%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $15.54
Upside: +80.18%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $27.63
Upside: +95.44%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.17
Upside: +26,370.59%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $15.21
Upside: +77.51%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $320.51
Upside: -57.26%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $7.14
Upside: +572.27%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $0.91
Upside: +3,190.56%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $63.20
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.63
Upside: -